137 related articles for article (PubMed ID: 1683780)
1. ICRF-187 (ADR-529) cardioprotection against anthracycline-induced cardiotoxicity: clinical and preclinical studies.
Green MD; Alderton P; Sobol MM; Gross J; Muggia FM; Speyer JL
Cancer Treat Res; 1991; 58():101-17. PubMed ID: 1683780
[No Abstract] [Full Text] [Related]
2. Late anthracycline cardiotoxicity protection by dexrazoxane (ICRF-187) in pediatric patients: echocardiographic follow-up.
Elbl L; Hrstkova H; Tomaskova I; Michalek J
Support Care Cancer; 2006 Feb; 14(2):128-36. PubMed ID: 16034614
[TBL] [Abstract][Full Text] [Related]
3. [The prevention of anthracycline-induced cardiomyopathy with a chelating agent (dexrazoxane = ICRF-187)].
Sauer H
Strahlenther Onkol; 1997 Jan; 173(1):51-2. PubMed ID: 9082586
[No Abstract] [Full Text] [Related]
4. [Cardioxan--a drug of prevention of anthracycline-related cardiotoxicity in pediatric oncology].
Kolygin BA
Vopr Onkol; 2002; 48(1):110-2. PubMed ID: 12101558
[No Abstract] [Full Text] [Related]
5. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.
Martin E; Thougaard AV; Grauslund M; Jensen PB; Bjorkling F; Hasinoff BB; Tjørnelund J; Sehested M; Jensen LH
Toxicology; 2009 Jan; 255(1-2):72-9. PubMed ID: 19010377
[TBL] [Abstract][Full Text] [Related]
6. [Prevention of anthracycline cardiotoxicity].
Rossetti R
Suppl Tumori; 2004; 3(4):S117-9. PubMed ID: 15206234
[No Abstract] [Full Text] [Related]
7. Cardioprotection by dexrazoxane (Cardioxane; ICRF 187): progress in supportive care.
Hellmann K
Support Care Cancer; 1996 Jul; 4(4):305-7. PubMed ID: 8829310
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the role of dexrazoxane as a cardioprotectant in cancer patients receiving anthracyclines.
Pouillart P
Cancer Treat Rev; 2004 Nov; 30(7):643-50. PubMed ID: 15531396
[TBL] [Abstract][Full Text] [Related]
9. Long-lasting effect of dexrazoxane against anthracycline cardiotoxicity in rats.
Della Torre P; Podesta A; Pinciroli G; Iatropoulos MJ; Mazué G
Toxicol Pathol; 1996; 24(4):398-402. PubMed ID: 8864181
[TBL] [Abstract][Full Text] [Related]
10. Doxorubicin-induced cardiomyopathy.
Muggia FM; Speyer JL
N Engl J Med; 1999 Feb; 340(8):654-5. PubMed ID: 10049088
[No Abstract] [Full Text] [Related]
11. Can dexrazoxane reduce myocardial injury in anthracycline-treated children with acute lymphoblastic leukemia?
Silber JH
Nat Clin Pract Oncol; 2004 Nov; 1(1):16-7. PubMed ID: 16264791
[No Abstract] [Full Text] [Related]
12. Role of (+-)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF-187) in modulating free radical scavenging enzymes in doxorubicin-induced cardiomyopathy.
Alderton P; Gross J; Green MD
Cancer Res; 1990 Aug; 50(16):5136-42. PubMed ID: 2116226
[TBL] [Abstract][Full Text] [Related]
13. [The use of Cardioxane in chemotherapy of malignant neoplasms in children].
Safonova SA; Punanov IuA; Dedukh VM; Kolygin BA
Vopr Onkol; 1997; 43(4):459-61. PubMed ID: 9381706
[TBL] [Abstract][Full Text] [Related]
14. Doxorubicin-induced myocardial injury.
Fujisaki G; Inokuchi C; Murashige N
N Engl J Med; 2004 Oct; 351(18):1908-9; author reply 1908-9. PubMed ID: 15509827
[No Abstract] [Full Text] [Related]
15. Dexrazoxane for the prevention of cardiomyopathy in anthracycline treated pediatric cancer patients.
Anderson B
Pediatr Blood Cancer; 2005 Jun; 44(7):584-8. PubMed ID: 15700251
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment with ICRF-187 provides long-lasting protection against chronic daunorubicin cardiotoxicity in rabbits.
Herman EH; Ferrans VJ
Cancer Chemother Pharmacol; 1986; 16(2):102-6. PubMed ID: 3081268
[TBL] [Abstract][Full Text] [Related]
17. Rationale and strategy for prevention of anthracycline cardiotoxicity with the bisdioxopiperazine, ICRF-187.
Green MD
Pathol Biol (Paris); 1987 Jan; 35(1):49-53. PubMed ID: 3550612
[TBL] [Abstract][Full Text] [Related]
18. Evidence of the selective alteration of anthracycline activity due to modulation by ICRF-187 (ADR-529).
Green MD; Alderton P; Gross J; Muggia FM; Speyer JL
Pharmacol Ther; 1990; 48(1):61-9. PubMed ID: 2125733
[TBL] [Abstract][Full Text] [Related]
19. Timing of treatment with ICRF-187 and its effect on chronic doxorubicin cardiotoxicity.
Herman EH; Ferrans VJ
Cancer Chemother Pharmacol; 1993; 32(6):445-9. PubMed ID: 8258192
[TBL] [Abstract][Full Text] [Related]
20. Examination of the potential long-lasting protective effect of ICRF-187 against anthracycline-induced chronic cardiomyopathy.
Herman EH; Ferrans VJ
Cancer Treat Rev; 1990 Sep; 17(2-3):155-60. PubMed ID: 2125530
[No Abstract] [Full Text] [Related]
[Next] [New Search]
